United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - natamycin (unii: 8o0c852cpo) (natamycin - unii:8o0c852cpo) - natacyn® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including fusarium solani keratitis. as in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. the effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. natacyn® (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

United States - English - NLM (National Library of Medicine)

eyevance pharmaceuticals, llc - natamycin (unii: 8o0c852cpo) (natamycin - unii:8o0c852cpo) - natacyn ® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including fusarium solani keratitis. as in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. the effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. natacyn ® (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed be

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

link healthcare sdn. bhd. - natamycin -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

link healthcare sdn. bhd. - natamycin -

Singapore - English - HSA (Health Sciences Authority)

link healthcare singapore pte ltd - natamycin - solution - 5.00% - natamycin 5%

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - natamycin - eye drops - 50mg/1ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - natamycin -

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

temmler italia s.r.l. - natamycin - suppositories vaginal - 100mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

temmler italia s.r.l. - natamycin, neomycin (neomycin sulfate), hydrocortisone (hydrocortisone micronized) - cream for external use - 10mg/g+3500u/g+10mg/g

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - natamycin - oral suspension - 1 % - active: natamycin